中文摘要：

目的：探讨血清抗氧化低密度脂蛋白抗体（抗oxLDL抗体）水平与糖尿病肾病进展和其微炎症状态的关系。方法：符合入选标准的健康人（NC组）21例，IgA肾病患者（IsAN组）18例，2型糖尿病不合并糖尿病肾病（尿白蛋白／尿肌酐＜30rag／g）患者（DM组）21例，糖尿病肾病患者（DN）62例。空腹采取静脉血，分离血清后-80℃冻存，ELISA法测定抗oxLDL抗体、高敏IL-6，免疫比浊法测定高敏C反应蛋白（hs—CRP）。比较各组患者血清抗oxLDL抗体水平的差异，并分析不同糖尿病肾病进展程度下血清抗oxLDL抗体水平变化的危险度。结果：（1）NC组、DM组、DN组和IgAN组间血清抗oxLDL抗体水平差异无明显统计学意义；血清CRP和IL-6水平，DM组、DN组和IgAN组明显高于NC组，DN组明显高于DM组。（2）与DM患者比较，早期DN（尿蛋白＜1g／d和GFR≥90ml／min）患者的血清抗oxLDL抗体水平升高的危险度显著增加；中期DN（尿蛋白1～3．5g／d和GFR30～89ml／min）患者的血清抗oxLDL抗体水平无明显变化；晚期DN（尿蛋白＞3．5g／d和GFR＜30ml／min）患者的血清抗oxLDL抗体水平降低的危险度明显增加。（3）血清抗oxLDL抗体水平与血清hs—CRP、IL-6和球蛋白水平呈明显正相关。结论：血清抗oxLDL抗体水平可作为早期糖尿病肾病的生物学标志，但不能预测糖尿病肾病进展；糖尿病肾病患者循环中的氧化水平与微炎症状态密切相关。

英文摘要：

Objective： To investigate serum antibody against oxidized low - density lipoprotein （ anti - oxLDL antibody） level in relation to the progress of diabetic nephropathies and microinflammatory state. Methods： According to selected criterion, subjects were divided into normal control subjects （ NC group） 21cases, IgA nephropathy patients （ IgAN group） 18 cases, Type 2 diabetes mellitus without diabetic nephropathies （urinary albumin/Urinary creatinine 〈30 mg/g）patients （DM group）21 cases, diabetic nephropa- thies patients （DN group）83 cases. The level of serum anti- oxLDL antibodies and High- sensitivity IL- 6 were measured by means of ELISA. High- sensitivityC-reactive protein（hsCRP） level was measured by Immune turbidimetry. We made comparisons of the level of serum anti - oxLDL antibodies among different groups, and analyzed the risk of different degrees of diabetic nephropathies to the level of serum anti - oxLDL antibodies. Results. （ 1 ） There is no difference about the serum anti - oxLDL antibodies level among NC gronp,DM group,DN group with lgAN group;the level of serum hs- CRP and IL-6 were significantly higher in the DM group, DN group and IgAN group than those in the NC group. Compared with DM group, the same data was obviously higher in the DN group. （2） Compared with DM group, early diabetic nephropathies（ proteinuria 〈1.0 g/d and GFR≥90 ml/min） group has increased risk of elevated level of serum anti - oxLDL antibodies ; Interim diabetic nephropathies （ proteinuria ： 1.0 - 3.5 g/d and GFR ： 30 ~ 89 mLemin） unrelated to the level of serum anti - oxLDL antibodies ; and advanced diabetic nephropathies （ proteinuria 〉 3.5 g/d and GFR 〈15 ml/min） has increased risk of reduced level of the same antibodies. （3） The serum anti - oxLDL antibodies level was significantly positively associated with the serum hsCRP, IL -6 and globulin level. Conclusion：The serum anti -oxLDL antibodies level can be used as a biological maker for early diabetic